礼来公司三年替西帕特结果显示持续减肥、糖尿病益处
Hawkinsight
2024-11-14 09:10:09
1.09W
jetcityimage/iStock社论，通过Getty Images
- More detailed results from Eli Lilly's (NYSE:LLY) three-year, phase 3 SURMOUNT-1 study showed that tirzepatide, the active ingredient in its obesity and type 2 diabetes meds, respectively, Wegovy and Ozempic, led to sustained weight loss and diabetes benefits.
- 经过三
免责声明：本文观点来自原作者，不代表Hawk Insight的观点和立场。文章内容仅供参考、交流、学习，不构成投资建议。如涉及版权问题，请联系我们删除。
